ETFs with VRTX as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.67%||iShares NASDAQ Biotechnology Index Fund (IBB)||+29.10 (15.23%)|
|2.65%||Vanguard S&P Mid-Cap 400 Growth ETF (IVOG)||+6.39 (7.70%)|
|1.43%||Vanguard Mid-Cap Growth ETF (VOT)||+5.83 (7.14%)|
|1.32%||Vanguard S&P Mid-Cap 400 ETF (IVOO)||+5.86 (7.16%)|
|0.53%||Vanguard Extended Market ETF (VXF)||+6.63 (8.98%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. Over the last two years, we have obtained approval for, and initiated commercial sales of, our first two products: INCIVEK (telaprevir), which we market in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which we market in the United States, Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation. We receive royalties from sales in Europe and other countries of telaprevir, which is marketed as INCIVO, by our collaborator, Janssen Pharmaceutica, N.V. We invest in scientific innovation to create transformative medicines for patients with serious diseases, with a focus on specialty markets. ... More ...